BackAnbio Biotechnology Class A Ordinary Shares Overview

Anbio Biotechnology Class A Ordinary Shares Receivables

Anbio Biotechnology Class A Ordinary Shares's receivables is $3.7M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$3.66M
↑ 243.44% YoYΔ $2.59M vs prior year quarter

Peer trimmed avg / median

Loading

Anbio Biotechnology Class A Ordinary Shares Receivables History

Loading

Anbio Biotechnology Class A Ordinary Shares vs. peers: Receivables Comparison

Loading

Anbio Biotechnology Class A Ordinary Shares Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Anbio Biotechnology Class A Ordinary Shares (NNNN) FAQ

As of the most recent data (December 2025), NNNN shows a receivables of $3.7M. That compares with $1.1M in the prior-year period — up 243.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NNNN's receivables is now $3.7M (was $1.1M) — a 243.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Anbio Biotechnology Class A Ordinary Shares is outperforming or lagging.

Tracking NNNN's receivables over time shows whether Anbio Biotechnology Class A Ordinary Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $3.7M That compares with $1.1M in the prior-year period — up 243.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Anbio Biotechnology Class A Ordinary Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $3.7M) with ownership activity and broader fundamentals.